SCHEMBL5584565

SCHEMBL5584565

COc1cccc2cc(C(=O)NNC(=O)c3ccccc3)oc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.72
NPC1 O15118 6/20 0.72
KMT2A Q03164 4/20 0.72
MEN1 O00255 3/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
LMNA P02545 1/20 0.63
RECQL P46063 1/20 0.63
HTT P42858 2/20 0.62
KDM4E B2RXH2 1/20 0.62
ALDH1A1 P00352 4/20 0.61
MAPT P10636 3/20 0.60
POLB P06746 4/20 0.58
HDAC1 Q13547 1/20 0.54
HDAC2 Q92769 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
HPGD P15428 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
CHRNA7 P36544 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5723065 0.84 RAB9A (1.00) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL6833294 0.83 RAB9A (0.66) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL5584864 0.82 LMNA (0.60) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL6241548 0.82 BCAT1 (0.63) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL5584871 0.81 KMT2A (0.72) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL6837896 0.81 KMT2A (0.63) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL978037 0.81 LMNA (0.77) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL6839243 0.81 NPC1 (0.74) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL5584678 0.79 LMNA (0.75) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL6837571 0.79 KMT2A (0.76) RAB9ANPC1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A RAB9A 2487/4885NPC1 2906/4885KMT2A 765/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A RAB9A 2487/4885NPC1 2906/4885KMT2A 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.